Neoleukin Therapeutics (NLTX) Financials

$3.49

$-10.47 (-75.00%)

As on 19-Dec-2023 09:30EDT

Market cap

$8 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

0.4

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Operating Revenue	--	--	0.01	0.45	--	25.00
Cost of Revenue	3.42	--	--	--	--	--
Gross Profit	-3.42	--	0.01	0.45	--	25.00
Operating Expenses	34.60	59.10	60.70	41.55	23.24	57.62
Operating Profit (EBIT)	-38.02	-59.10	-60.70	-33.73	-70.96	-32.62
Other Income	-0.01	--	0.01	0.45	1.52	1.04
Profit before Tax	-34.26	-57.56	-60.69	-33.28	-69.44	-31.59
Provision for Tax	5.10	-1.54	-2.28	-8.32	-0.01	-1.04
Profit after Tax (Net Income)	-39.36	-56.02	-58.42	-24.96	-69.44	-31.59
Minority Interest	--	--	--	--	--	--
Consolidated Profit	-29.73	-57.56	-60.69	-33.28	-69.44	-31.59

Liabilities ($ Mln)	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Shareholder's Funds	75.24	94.33	142.86	191.22	141.69	72.67
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	9.14	10.56	11.76	11.41	0.59	0.32
Current Liabilities	5.21	11.06	8.64	7.89	4.74	4.63
Total Liabilities	94.80	115.95	163.26	210.52	147.02	77.62

Assets ($ Mln)	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Non-Current Assets	9.69	16.81	19.27	16.00	3.43	0.45
Current Assets	79.89	99.13	143.99	194.52	143.60	77.17
Total Assets	94.80	115.95	163.26	210.52	147.02	77.62
Total Debt*	10.69	12.07	12.98	12.12	1.21	0.01
Net Current Assets	74.68	88.07	135.35	186.63	138.85	72.54

Cashflow ($ Mln)	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Cash From Operating Activities	--	-45.61	-47.56	-24.58	-15.39	-31.58
Cash Flow from Investing Activities	--	-59.13	-3.26	-2.22	-0.69	55.95
Cash from Financing Activities	--	0.16	0.73	77.14	82.24	0.57
Net Cash Inflow / Outflow	--	--	-50.09	50.34	66.16	24.94

Financials Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Adjusted EPS ($)	-2.64	-1.01	-1.06	-0.46	-1.41	-1.34
Cash EPS ($)	--	-0.97	-1.02	-0.43	-1.41	-1.34
Adjusted Book Value ($)	--	1.71	2.59	3.53	2.88	3.09
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	-0.82	-0.86	-0.45	-0.31	-1.34
Free Cash Flow per Share ($)	--	-0.85	-0.92	-0.50	-0.33	-1.34

Profitability Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
ROCE (%)	--	-42.72	-32.53	-14.42	-64.42	-36.81
ROE (%)	-54.63	-47.23	-34.97	-14.99	-64.78	-36.82
ROA (%)	-33.99	-40.13	-31.26	-13.96	-61.82	-33.61
EBIT Margin (%)	--	--	-1,011,633.33	-7,478.49	--	-130.20
Net Margin (%)	281,135.71	--	-486,791.67	-2,766.74	-4,574.11	-121.28
Cash Profit Margin (%)	--	--	--	--	--	--

Growth Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Revenue Growth (%)	--	-1.00	-0.99	--	-1.00	--
EBIT Growth (%)	36.65	2.64	-79.96	52.47	-118.01	36.30
Net Profit Growth (%)	26.72	4.11	-134.07	64.06	-119.84	37.06
EPS Growth (%)	-34.12	0.04	-1.30	0.67	-0.05	0.37
Book Value Growth (%)	-29.11	--	--	--	--	--

Valuation Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Price / Earnings	--	-0.50	-4.55	-30.58	-8.72	-1.61
Price / Book Value	0.44	0.30	1.86	3.99	4.28	0.70
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	1.07	0.99	-2.33	-12.25	-21.71	0.83
Close Price ($)	15.80	10.18	96.40	282.00	246.40	43.20
High Price ($)	18.80	107.00	317.80	362.60	268.60	338.00
Low Price ($)	7.50	7.50	92.00	116.20	42.80	39.20
Market Cap ($ Cr)	8.20	--	--	--	--	--

Solvency Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Debt to Equity	--	0.13	0.09	0.06	0.01	0.00
Short term debt to equity ratio	0.02	0.02	0.01	0.00	0.00	--
Current Ratio	15.33	8.96	16.67	24.66	30.28	16.68
Quick Ratio	15.33	--	--	--	--	--
Interest Coverage	-11.56	-37.36	-3,194.63	-68.83	-70,959.00	-8,137.25

Operating Efficiency Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Debtors to sales (%)	--	--	--	199.56	--	0.95
Asset Turnover	--	--	0.00	0.00	--	0.27
Receivable days	--	--	54,787.50	568.12	--	7.14
Inventory Days	--	--	--	--	--	--
Payable days	--	--	--	--	--	--
Cash Conversion Cycle	--	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.